O-GLCNACYLATION TREATMENT FOR ISCHEMIC BRAIN INJURY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 28, 2016
app pub date -
Jul 24, 2015
filing date -
Jul 28, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Cerebral ischemia-reperfusion injury may be treated by compounds that increase brain O-GlcNAcylation, such as a therapeutic amount of a compound that increases the hexosamine biosynthesis pathway flux that bypasses glutamine/fructose-6-phosphate amidotransferase 2 or a therapeutic amount of a compound that inhibits OGA. The initial and transient elevation of brain O-GlcNAcylation is neuroprotective and helps ameliorate cerebral ischemia-reperfusion injury when administered within three hours of the ischemia-reperfusion-induced brain injury and continues for at least two days.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully